<DOC>
	<DOC>NCT00175903</DOC>
	<brief_summary>Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.</brief_summary>
	<brief_title>Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Diagnosis of epilepsy (all types of seizures) was made during the past year Subjects must have had at least two unprovoked seizures in the past 2 years with at least one during the last 6 months Female subjects without childbearing potential are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method Subjects previously allocated to a trial treatment (CBZ, VPA and LEV) used in this trial Participation in another clinical trial with an investigational drug or device within 12 weeks of the selection visit (V1), or at any time during this trial Pregnant or lactating women Presence of known pseudoseizures within the last year Uncountable seizures (clusters) or history of convulsive status epilepticus Any disorder or condition that may interfere with the absorption, distribution, metabolisation or excretion of drugs History of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous five years Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors Presence of a terminal illness or any medical condition that might interfere with the subject's trial participation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Newly Diagnosed Epilepsy</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
	<keyword>Carbamazepine</keyword>
	<keyword>Valproate</keyword>
</DOC>